Rilpivirine Hydrochloride Patent Expiration
Rilpivirine Hydrochloride is Used for treating HIV-1 infection in treatment-naive adult patients with low viral load. It was first introduced by Janssen Products Lp
Rilpivirine Hydrochloride Patents
Given below is the list of patents protecting Rilpivirine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Edurant Ped | US11065198 | Dispersible compositions | Oct 23, 2037 | Janssen Prods |
| Edurant |
US7125879 (Pediatric) | HIV inhibiting pyrimidines derivatives | Oct 21, 2025 | Janssen Prods |
| Edurant | US7125879 | HIV inhibiting pyrimidines derivatives | Apr 21, 2025 | Janssen Prods |
| Edurant Ped | US7125879 | HIV inhibiting pyrimidines derivatives | Apr 21, 2025 | Janssen Prods |
| Edurant | US7638522 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr 14, 2023
(Expired) | Janssen Prods |
| Edurant | US8080551 | HIV inhibiting pyrimidines derivatives |
Apr 11, 2023
(Expired) | Janssen Prods |
| Edurant | US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug 09, 2022
(Expired) | Janssen Prods |
| Edurant | US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb 26, 2021
(Expired) | Janssen Prods |
| Edurant | US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec 20, 2019
(Expired) | Janssen Prods |
Rilpivirine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List